Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ovid TherapeuticsOVID +1.06%34 Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus rates OVID with a GF Score™ of 34/100 and a GF Value™ of $0.98 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 839 Biotechnology companies, Ovid Therapeutics ranks worse than 119189.39% on this metric.
The historical rank and industry rank for Ovid Therapeutics's Days Sales Outstanding or its related term are showing as below:
OVID's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 69.33 * Ranked among companies with meaningful Days Sales Outstanding only.
Ovid Therapeutics's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
Ovid Therapeutics (NAS:OVID) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Ovid Therapeutics Days Sales Outstanding Related Terms
Ovid Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Ovid Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OVID vs SGMT, CABA, QTTB: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Ovid Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's Days Sales Outstanding falls into.
Ovid Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics (OVID) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ovid Therapeutics and its competitors. According to the industry distribution chart, Ovid Therapeutics ranks #999999 out of 839 companies in the Biotechnology industry.
Is Ovid Therapeutics' Days Sales Outstanding too high?
Ovid Therapeutics' current Days Sales Outstanding is 0.00. Based on the distribution chart, Ovid Therapeutics ranks #999999 out of 839 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ovid Therapeutics has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' Days Sales Outstanding compare to SGMT and CABA?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #999999 out of 839 companies for Days Sales Outstanding. This places Ovid Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 69.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.33, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ovid Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovid Therapeutics's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.98, compared to a current price of $2.85 — trading 190.8% above its estimated fair value. The current Days Sales Outstanding is 0.00. Ovid Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (OVID) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be overvalued.
The current stock price of $2.85 is trading 190.8% above its estimated GF Value™ of $0.98.
GuruFocus considers Ovid Therapeutics to be Significantly Overvalued.
Key valuation signals for OVID:
Days Sales Outstanding: 0.00
GF Value™: $0.98 vs. price of $2.85 (190.8% above fair value)
No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
34GF Score
Get the complete analysis for OVID
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVID has been successfully added to your 
